Hepatitis B Reactivation Prompts New Warnings for Arzerra, RituxanMonthly Prescribing ReferenceThe FDA has approved changes to the prescribing information for Arzerra (ofatumumab; GlaxoSmithKline) and Rituxan (rituximab; Genentech) to add a new warning…
Recommendations help physicians in treating systemic juvenile arthritisToronto NewsFIX… the use of Non-steroidal anti-inflammatory drugs (NSAIDs), Glucocorticoids, Methotrexate, Leflunomide, Intravenous immunoglobulin (IVIG), Calcineurin inhibitors, …
Clinical Oncology NewsDose-Dense Regimen Does Not Improve R-CHOP for DLBCLClinical Oncology NewsThe addition of rituximab (Rituxan, Genentech) to the regimen (i.e., R-CHOP) was found to improve cure rates by 10% to 15%. Researchers from the United King…
Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve …PR Web (press release)Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid a…
|
BioLineRx Ltd.’s BL-8040 Receives Orphan Drug Designation for Treatment of …
Lifescience-online Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from … |
MedPage TodayEpilepsy Has Immune Origin in Some PatientsMedPage TodayEleven of the IgG-positive patients were offered immunotherapies based on intravenous methylprednisolone plus other treatments — donor immunoglobulins, rituximab (Rituxan), or plasma…
|
Difficulties in extending patent protection for uses of known drugs in Europe …
Lexology (registration) A case in point is the recent EPO Board of Appeals decision in T0734/12 in relation to a patent (EP1613350) in which Genentech claimed use of rituximab (Rituxan®) to treat patients who were suffering from rheumatoid arthritis (RA) who were refractory … |
|
Enbrel, Humira “still mainstay” first-line US RA biologics
PharmaTimes In addition, treating physicians told the study that they would consider switching 22%-34% of their patients who are currently being treated with Orencia IV, and 20%-25% of their patients who are receiving Genentech/Biogen Idec’s Rituxan (rituximab) or … |
Clinical Oncology NewsLenalidomide Indication Expanded To Include MCLClinical Oncology NewsThe expanded indication is based on the results of MCL-001, a Phase II, multicenter, open-label, single-arm trial that included 134 patients with MCL who had rec…
Drug Discovery & Development |
FDA OKs Teva’s New Treanda Liquid Formulation
Drug Discovery & Development Treanda is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia (CLL). |